The Medicines Company
The 10-second takeaway
For the quarter ended June 30 (Q2), The Medicines Company beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. Non-GAAP earnings per share grew. GAAP earnings per share grew significantly.
Gross margins dropped, operating margins grew, net margins grew.
The Medicines Company notched revenue of $172.8 million. The 10 analysts polled by S&P Capital IQ predicted sales of $168.7 million on the same basis. GAAP reported sales were 27% higher than the prior-year quarter's $135.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.50. The eight earnings estimates compiled by S&P Capital IQ predicted $0.48 per share. Non-GAAP EPS of $0.50 for Q2 were 8.7% higher than the prior-year quarter's $0.46 per share. GAAP EPS of $0.30 for Q2 were 20% higher than the prior-year quarter's $0.25 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 63.0%, 550 basis points worse than the prior-year quarter. Operating margin was 16.7%, 230 basis points better than the prior-year quarter. Net margin was 10.5%, 40 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $173.9 million. On the bottom line, the average EPS estimate is $0.59.
Next year's average estimate for revenue is $686.3 million. The average EPS estimate is $1.92.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 161 members out of 177 rating the stock outperform, and 16 members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give The Medicines Company a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on The Medicines Company is outperform, with an average price target of $37.95.
- Add The Medicines Company to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.